These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8690819)

  • 1. The effects of epoprostenol on drug disposition. I: A pilot study of the pharmacokinetics of digoxin with and without epoprostenol in patients with congestive heart failure.
    Carlton LD; Patterson JH; Mattson CN; Schmith VD
    J Clin Pharmacol; 1996 Mar; 36(3):247-56. PubMed ID: 8690819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of epoprostenol on drug disposition. II: A pilot study of the pharmacokinetics of furosemide with and without epoprostenol in patients with congestive heart failure.
    Carlton LD; Patterson JH; Mattson CN; Schmith VD
    J Clin Pharmacol; 1996 Mar; 36(3):257-64. PubMed ID: 8690820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologic pharmacokinetic modeling of gastrointestinal blood flow as a rate-limiting step in the oral absorption of digoxin: implications for patients with congestive heart failure receiving epoprostenol.
    Carlton LD; Pollack GM; Brouwer KL
    J Pharm Sci; 1996 May; 85(5):473-7. PubMed ID: 8742937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of digoxin in Japanese patients: a 2-compartment pharmacokinetic model.
    Yukawa E; Suematu F; Yukawa M; Minemoto M; Ohdo S; Higuchi S; Goto Y; Aoyama T
    Clin Pharmacokinet; 2001; 40(10):773-81. PubMed ID: 11707062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of itraconazole on digoxin clearance in patients with congestive heart failure].
    Wakasugi H; Ishizuka R; Koreeda N; Yano I; Futami T; Nohara R; Sasayama S; Inui K
    Yakugaku Zasshi; 2000 Sep; 120(9):807-11. PubMed ID: 11019654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of two-point assay of digoxin serum concentration in studying population pharmacokinetics in Egyptian pediatric patients with heart failure: does it make sense?
    el-Desoky ES; Madabushi R; Amry Sel-D; Bhattaram VA; Derendorf H
    Am J Ther; 2005; 12(4):320-7. PubMed ID: 16041195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic analysis of digoxin in Chinese neonates and infants.
    Gong Y; Chen Y; Li Q; Li Z
    J Pharmacol Sci; 2014; 125(2):142-9. PubMed ID: 24837877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of digoxin clearance in Japanese elderly patients for optimization of drug therapy: a population pharmacokinetics analysis using nonlinear mixed-effects modelling.
    Yukawa M; Yukawa E; Suematsu F; Takiguchi T; Ikeda H; Aki H; Mimemoto M
    Drugs Aging; 2011 Oct; 28(10):831-41. PubMed ID: 21970310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of digoxin in elderly patients.
    Chen R; Zou SL; Wang ML; Jiang Y; Xue H; Qian CY; Xia ZL
    Eur J Drug Metab Pharmacokinet; 2013 Jun; 38(2):115-21. PubMed ID: 23096939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of digoxin in Egyptian pediatric patients: impact of one data point utilization.
    EL Desoky ES; Nagaraja NV; Derendorf H
    Am J Ther; 2002; 9(6):492-8. PubMed ID: 12424506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).
    Califf RM; Adams KF; McKenna WJ; Gheorghiade M; Uretsky BF; McNulty SE; Darius H; Schulman K; Zannad F; Handberg-Thurmond E; Harrell FE; Wheeler W; Soler-Soler J; Swedberg K
    Am Heart J; 1997 Jul; 134(1):44-54. PubMed ID: 9266782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of digoxin in children with congestive heart failure aggravated by other diseases.
    Lares-Asseff I; Juárez-Olguín H; Flores-Pérez J; Bobadilla-Chávez J
    Rev Invest Clin; 2004; 56(1):32-7. PubMed ID: 15144040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic investigation of digoxin in Japanese infants and young children.
    Yukawa M; Yukawa E; Suematsu F; Takiguchi T; Ikeda H; Aki H; Mimemoto M
    J Clin Pharmacol; 2011 Jun; 51(6):857-63. PubMed ID: 20592416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoepidemiologic detection of calcium channel blocker-induced change on digoxin clearance using multiple trough screen analysis.
    Suematsu F; Yukawa E; Yukawa M; Minemoto M; Ohdo S; Higuchi S; Goto Y
    Biopharm Drug Dispos; 2002 Jul; 23(5):173-81. PubMed ID: 12116048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of angiotensin-converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure. SAGE Study Group. Systematic Assessment of Geriatric drug use via Epidemiology.
    Gambassi G; Lapane KL; Sgadari A; Carbonin P; Gatsonis C; Lipsitz LA; Mor V; Bernabei R
    Arch Intern Med; 2000 Jan; 160(1):53-60. PubMed ID: 10632305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population analysis for the optimization of digoxin treatment in Japanese paediatric patients.
    Suematsu F; Minemoto M; Yukawa E; Higuchi S
    J Clin Pharm Ther; 1999 Jun; 24(3):203-8. PubMed ID: 10438180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay.
    Cheng JW; Charland SL; Shaw LM; Kobrin S; Goldfarb S; Stanek EJ; Spinler SA
    Pharmacotherapy; 1997; 17(3):584-90. PubMed ID: 9165563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Community pharmacist outreach program directed at physicians treating congestive heart failure.
    Turner CJ; Parfrey P; Ryan K; Miller R; Brown A
    Am J Health Syst Pharm; 2000 Apr; 57(8):747-52. PubMed ID: 10786260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure.
    Luzier AB; Forrest A; Adelman M; Hawari FI; Schentag JJ; Izzo JL
    Am J Cardiol; 1998 Aug; 82(4):465-9. PubMed ID: 9723634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of levosimendan in patients with congestive heart failure.
    Jonsson EN; Antila S; McFadyen L; Lehtonen L; Karlsson MO
    Br J Clin Pharmacol; 2003 Jun; 55(6):544-51. PubMed ID: 12814448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.